Broaden your knowledge by attending an Industry-Supported Symposium. Preregistration for these courses is recommended; walk-ins are welcome as space allows. Check the meeting app for the most up-to-date schedule.
Industry-Supported Symposia are independently organized and are not an official part of the Internal Medicine Meeting 2026 Education Program. For Symposia offering Category 1 CME credit, CME is provided by organizations other than ACP. Live-streamed sessions will be available for 30 days after the meeting.
Tuesday, April 14
Lunch
RSV Disease in Adults: Epidemiology, Clinical Burden and Prevention
Supported by: Pfizer Inc.
12:15-1:15 p.m. • Registration: Noon
CC • 9-12
Presentation: In-person only
(Preregistration is recommended; walk-ins are welcome as space allows.)
RSV causes significant burden among older and at-risk adults and is associated with cardiovascular sequelae. RSV vaccines were shown to be effective in clinical trials, against RSV-related lower respiratory tract disease, and, since licensure, effectiveness has been evaluated in several real-world settings. This symposium provides an overview of the burden of RSV infection in older adults, noting the epidemiology and clinical sequelae, specifically cardiovascular sequelae, as well as reviewing preventative measures. Several real-world vaccine effectiveness analyses conducted in diverse populations are discussed. These presentations and moderator-led discussion aim to update attendees with data relevant to their clinical practice.
This program does not offer CME credit.
Team Trivia! Are You Keeping Up with Pneumococcal Disease and Vaccine Developments?
Supported by: Merck
12:15-1:15 p.m. • Registration: Noon
CC • 20-23
Registration: https://deceraclinical.com/education/2026KeepUpWithPCV
Presentation: In-person only
(Preregistration is recommended; walk-ins are welcome as space allows.)
This trivia game-based activity, featuring 2 expert faculty, will provide unique insights on the latest developments in pneumococcal disease prevention including key epidemiological data, developments in pneumococcal conjugate vaccines and recommendations, and strategies to optimize disease prevention amidst the headwinds of misinformation and vaccine hesitancy.
Wednesday, April 15
Lunch
Hidden in Plain Sight: Recognizing and Referring Patients with Transthyretin Cardiac Amyloidosis in Internal Medicine
Supported by: Alnylam Pharmaceuticals, Inc.
12:15-1:15 p.m. • Registration: Noon
CC • 9-10
Registration: https://PeerView.com/ATTR26-Live
Presentation: In-person only
(Preregistration is recommended; walk-ins are welcome as space allows.)
Transthyretin amyloidosis (ATTR) is a progressive disease where amyloid fibrils accumulate in various organs and tissues, leading to organ dysfunction, disability, and death. ATTR affecting the heart is known as ATTR cardiac amyloidosis (ATTR-CA) and can be mistaken for other more common causes of heart failure. While targeted therapies can help slow disease progression, early diagnosis and treatment initiation are key to achieving the best outcomes.
Internal medicine clinicians are in a unique position to identify these patients early and refer them for specialty care. Two expert cardiologists, Julie L. Rosenthal, MD, FACC, and Ronald Witteles, MD, will share valuable insights on how to effectively approach ATTR-CA in everyday practice. Register now and gain the tools you need to uncover what’s hidden in plain sight!
Internal Medicine Live! Modern Vaccine Approaches Amidst Contemporary Driving Forces
Supported by: Merck
12:15-1:15 p.m. • Registration: Noon
CC • 20-23
Registration: https://deceraclinical.com/education/2026VaccineApproaches
Presentation: In-person only
(Preregistration is recommended; walk-ins are welcome as space allows.)
This 60-minute CME/CPE/CE/ABIM MOC–certified live “talk show” format presentation will feature engaging and candid interviews between a panel of renowned vaccine experts and a host, with audience participation, on contemporary vaccine topics including navigating vaccine misinformation and attention economy in the age of social media, effective and ineffective strategies to navigate vaccine hesitancy, and answers to frequently asked questions around vaccine safety and effectiveness.
Dinner
New Pathways to Early Detection and Intervention in Alzheimer’s Disease
Sponsored by: Lilly
6:30-8:00 p.m. • Registration: 6:00 p.m.
InterContinental San Francisco • Grand Ballroom C
Registration: www.MLG-AD.com
Presentation: In-person, Livestream, and On Demand
(Preregistration is recommended; walk-ins are welcome as space allows.)
This satellite symposium program will equip clinicians with practical, evidence-based strategies to enhance early identification and management of mild cognitive impairment (MCI) and Alzheimer’s disease (AD). A leading neurologist and primary care clinician will review integrated approaches to screening, diagnosis, and staging that combine clinical assessment with objective cognitive and biomarker testing. Participants will examine current clinical practice recommendations for disease-modifying therapies, including appropriate patient selection, monitoring, and management of adverse events such as ARIA. Emphasis is placed on multidisciplinary care and shared decision-making to support patient-centered AD management.
Unlocking the Potential of Incretin-Based Therapies in Comprehensive Cardiometabolic Care
Supported by: Lilly
6:30-8:00 p.m. • Registration: 6:00 p.m.
Hyatt Regency San Francisco Downtown SOMA • Gallery Ballroom
Registration: https://www.PeerView.com/T2DSanFran26-Live
Presentation: In-person, Livestream, and On Demand
(Preregistration is recommended; walk-ins are welcome as space allows.)
Despite advances in the therapeutic armamentarium for type 2 diabetes (T2D), gaps in care for people with T2D (PwT2D) continue to hinder optimal glycemic control and increase the likelihood of diabetes-related complications including cardiovascular (CV) disease, microvascular disease, and mortality. Fewer than one in four PwT2D at high CV risk are receiving evidence-based therapies shown to reduce CV events in major outcomes trials, including incretin-based agents.
There is a pressing need for targeted, practical education to help primary care professionals apply current evidence effectively and overcome clinical inertia and fragmented care. As new incretin-based treatments demonstrate potential to reduce A1C, induce weight loss, lower CV risk, boost adherence with oral options, and improve overall outcomes, their timely and appropriate use in practice is critical.
Advancing Cardio-Kidney-Metabolic Care in Internal Medicine: Evidence-based Guidance for Incorporating Nonsteroidal MRAs
Supported by: Bayer HealthCare Pharmaceuticals Inc.
6:30-7:30 p.m. • Registration: 6:00 p.m.
InterContinental San Francisco • Grand Ballroom AB
Registration: www.answersincme.com/101064703
Presentation: In-person only
(Preregistration is recommended; walk-ins are welcome as space allows.)
Stay on the leading edge of cardio-kidney-metabolic (CKM) care and the use of non-steroidal mineralocorticoid receptor antagonists (nsMRAs) as a standard component of treatment. Our experts will explore the latest evidence for nsMRAs in managing heart failure (HF), including HF with preserved ejection fraction (HFpEF) and with mildly reduced ejection fraction (HFmrEF), in patients with or without overlapping chronic kidney disease (CKD) and type 2 diabetes (T2D). Keep up-to-date on evidence-based best practices for managing your patients with HF. Don't miss this opportunity to enhance your expertise and position yourself at the forefront of evolving HF care that delivers durable, long-term benefits across CKM conditions.
Thursday, April 16
Dinner
Reaching New Heights In Cardio-Renal-Metabolic Care: Optimizing Treatment to Elevate Patient Outcomes
Supported by: Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company
6:30 – 8:00 p.m. • Registration: 6:00 p.m.
San Francisco Marriott Marquis • Yerba Buena Ballroom, Salon 9
Registration: https://www.deceraclinical.com/education/cvrmSanFrancisco2026
Presentation: In-person only
(Preregistration is recommended; walk-ins are welcome as space allows.)
Despite advances in treatment, patients with cardio-renal-metabolic (CRM) conditions such as diabetes, CKD and heart failure remain at exceptionally high risk for disease progression and adverse outcomes. Internal medicine healthcare professionals (HCPs) have an increasing role as gatekeepers for managing patients with CRM diseases and ensuring timely initiation of evidence-based therapies. However, clinical inertia continues to limit optimal care delivery, with hesitancy among HCPs and patients to follow guideline-directed medical therapy (GDMT). Join our expert faculty as they discuss the importance of GDMT and action steps that can improve outcomes for your patients with CRM diseases.
From Numbers to Navigation: Translating CGM Data into Optimized Decision-Making
Supported by: Abbott Diabetes Care, Inc.
6:30 – 8:00 p.m. • Registration: 6:00 p.m.
San Francisco Marriott Marquis • Yerba Buena Ballroom, Salon 7
Registration: https://www.gotoper.com/courses/from-numbers-to-navigation-translating-cgm-data-into-optimized-decision-making
Presentation: In-person, Livestream, and On Demand
(Preregistration is recommended; walk-ins are welcome as space allows.)
This will be a dynamic educational symposium focused on the state of the art in technology-driven diabetes monitoring and will explore the latest advances in continuous glucose monitoring (CGM) and ketone monitoring, highlighting how these tools are reshaping clinical decision-making and day-to-day diabetes management. Expert faculty—recognized clinician–researchers in the field—will present the current state of the science, translate emerging evidence into practical strategies, and share real-world insights to support optimal patient outcomes.
Lipoprotein(a): Actionable Insights for Primary Prevention
Supported by: Lilly Medical
7:00 – 8:00 p.m. • Registration: 6:45 p.m.
San Francisco Marriott Marquis • Yerba Buena Ballroom, Salon 8
Presentation: In-person only
(Preregistration is recommended; walk-ins are welcome as space allows.)
Join us to discover why Lp(a) testing is essential for elevating patient care. This session will cover how a cardiologist and a primary care physician could implement lipoprotein(a) [Lp(a)] testing to better assess and manage cardiovascular risk for patients in their clinical practice. Following this session, you will be equipped to confidently leverage Lp(a) testing results to optimize patient care in your own practice.
This program does not offer CME credit.
Friday, April 17
Dinner
Advancing Heart Failure and CKD Care Through Aldosterone Modulation: Emerging Strategies for Practice Provider
Supported by: Boehringer Ingelheim Pharmaceuticals, Inc.
6:30 – 8:00 p.m. • Registration: 6:00 p.m.
San Francisco Marriott Marquis • Yerba Buena Ballroom, Salon 7
Registration: http://www.mycme.com/HF-CKD2026
Presentation: In-person only
(Preregistration is recommended; walk-ins are welcome as space allows.)
Join a panel of three renowned clinical experts for a dynamic and engaging CME dinner symposium that delves into the latest advances in care for patients with complex heart failure and chronic kidney disease. You will gain critical insights into the role of aldosterone and evidence-based strategies for identification and therapeutic options, including adjuncts to SGLT2 inhibitors. Moving beyond didactic lectures, the dynamic format features interactive "Clinical Conundrums" case discussions, allowing you to practice clinical decision-making and immediately apply new, guideline-directed strategies at the point of care.
Golden Gate to Glycemic Control in T2D: Bridging the Gap Between Insulin Innovations and Primary Care Practice
Supported by: Lilly
6:30 – 7:30 p.m. • Registration: 6:00 p.m
San Francisco Marriott Marquis • Yerba Buena Ballroom, Salon 8
Registration: https://InsulinInnovations.eventbrite.com
Presentation: In-person only
(Preregistration is recommended; walk-ins are welcome as space allows.)
Despite an expanding treatment landscape, many patients with type 2 diabetes (T2D) continue to experience suboptimal glycemic control, highlighting the need to optimize insulin-based management strategies. Emerging once-weekly basal insulin formulations may address limitations of once-daily analogues by simplifying regimens and supporting medication adherence.
Primary care practitioners (PCPs) play a central role in initiating, titrating, and adjusting insulin therapy alongside other antidiabetic agents, yet practical education on evolving insulin formulations remains limited. This case-based educational initiative is designed to prepare PCPs for the potential role of once-weekly basal insulin while reinforcing core insulin management principles. Delivered through an interactive game show format, learners will engage in team-based treatment decision challenges guided by expert faculty and evidence-based discussion.
Missed Opportunities in Menopause Management: Advancing Relief for VMS and Sleep
Supported by: Bayer HealthCare Pharmaceuticals Inc.
6:30 – 8:00 p.m. • Registration: 6:00 p.m.
San Francisco Marriott Marquis • Yerba Buena Ballroom, Salon 9
Registration: https://deceraclinical.com/education/SanFranVMS2026
Presentation: In-person only
(Preregistration is recommended; walk-ins are welcome as space allows.)
In the US, women in menopause comprise a substantial proportion of the population, with more than 1 million entering menopause each year. It is estimated that ≥80% of women in menopause experience disruptive symptoms, including vasomotor symptoms (hot flashes, night sweats) and sleep disturbances, that can significantly compromise daily function, impair health, and reduce quality of life. Internal medicine healthcare professionals (HCPs) are uniquely positioned to help patients navigate symptom management in the menopause transition. However, limited training in menopause care and lack of information on treatment innovations lead to missed intervention opportunities. Please join our expert faculty as they provide insights for improving menopause management, focusing on recognition of clinical manifestations, integration of evidence on current treatment options, and approaches for effective communication.